Conclusions: Expression of LILRB3 correlates with disease activity of RA and is decreased after successful treatment with DMARDS or biologicals. Since LILRB3 is an inhibiting receptor the increased expression in active RA may be a counterregulation to reduce disease activity. Methods: The effector characteristics of peripheral blood CD8 T cells were evaluated by flow cytometry. RA patients with established (n=21) and early disease (n=20) were recruited, and compared to twenty four healthy controls. The mean age of the subjects was 59 (SD=12.5), 25/38 (66%) were female, 27/38 (71%) were anti-CCP positive and 25/38 (66%) rheumatoid factor positive. The mean age for the controls was 43 (SD=11.6), 14/20 (70%) were female. Results: Confirming our previous work, a significantly higher proportion of CD3+CD8+CD28-cells was observed in RA patients compared to healthy individuals (P=0.03) (Figure 1 ). Flow cytometric evaluation of peripheral blood demonstrated a significantly higher expression of CD57, CD45Ra and KLRG1 in CD28-compared to CD28+ T cells. A further evaluation of these markers revealed that 69% of the CD8+CD28-cell pool was KLRG1+, in comparison to 66% being CD57+ and 55% KLRG1+CD57+ double positive. This suggests that KLRG1 is a robust and clinically relevant marker of CD28-T cells in RA. Our current research is investigating the significance of KLRG1 and CD8+CD28-cells as prognostic markers in RA.
Conclusions: CD3+CD8+CD28-cells are enriched in the peripheral blood of RA patients. KLRG1 expression is increased in line with CD57 and CD45Ra in CD8+CD28-cells, and will be used to evaluate the functional significance of these cells in relation to their activation status and potential senescence in the immunoregulation of RA pathogenesis. 
